This patient registry will capture data from patients who have been or who are undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their routine clinical care. The registry will shed light on real-world outcomes of safety and efficacy of the procedure and understand how a patient's quality of life is affected throughout their follow-up and lifetime.
Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.
Profound Medical (PRN) is the sponsoring company for this trial. BiotechSign currently grades this company D (46/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.